For Immediate Release
Chicago, IL –March 6, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Boeing (BA - Free Report) , Abbott (ABT - Free Report) , PayPal (PYPL - Free Report) , Caterpillar (CAT - Free Report) and Anthem (ANTM - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Boeing, Abbott and PayPal
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boeing, Abbott and PayPal. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Strong Buy-ranked Boeing’s shares have gained +34.2% year to date, outperforming the S&P 500, which increased +11.4% during the same time period. The company’s 20-year market outlook forecasts commercial jetliner demand to increase by 4.1%, with single-aisle jets being the major driver behind this demand growth.
Boeing expects the commercial fleet to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes. The Zacks analyst thinks Boeing’s strong balance sheet and cash flows provide financial flexibility in matters of incremental dividend, ongoing share repurchases and earnings accretive acquisitions.
Its revenue exposure is also spread across more than 90 countries around the globe. However, this aerospace giant may face competitive challenges once new manufacturers like China enters the commercial jet space.
(You can read the full research report on Boeing here >>>).
Shares of Abbott have gained +9.9% over the past three months, outperforming the S&P 500, which has increased +3.6% over the same period. Abbott exited the fourth quarter on a mixed note with earnings in line with expectations and revenues missing the mark. Increasing currency headwinds to some extent dented the company’s international performance.
Meanwhile, emerging market performance has been promising. The Zacks analyst is optimistic about the strong and consistent performance by the company’s EPD and Medical Devices segments organically. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip improves further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Vascular arm in the United States continues to dent growth.
(You can read the full research report on Abbott here >>>).
PayPal’s shares have outperformed the S&P 500 in the past year (+22.1% vs. +2.6%). The Zacks analyst thinks PayPal’s rising transaction revenues, growth in active customer accounts and benefits from acquisitions of Hyperwallet and iZettle remain growth drivers. Further, Venmo’s improving monetization efforts, partnerships and its increasing adoption rate across various platforms are aiding the company’s user base.
Strong momentum of PayPal in international markets, especially in India and Japan remained a major positive. However, adverse foreign exchange translations, competition from Square and interest rate risks are concerns. Further, sale of the credit portfolio to Synchrony is expected to continue impacting negatively. Also, a challenging macroeconomic environment in China and the UK remain concerns.
(You can read the full research report on PayPal here >>>).
Other noteworthy reports we are featuring today include Caterpillar and Anthem.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.